

## *Supplementary Material*

### **Antagonism of CGRP signaling by rimegepant at two receptors**

**Kylie S Pan<sup>1</sup>, Andrew Siow<sup>2</sup>, Debbie L Hay<sup>1,3,4,5\*</sup>, Christopher S Walker<sup>1,3,4\*</sup>**

<sup>1</sup> School of Biological Sciences, University of Auckland, Auckland, New Zealand.

<sup>2</sup> School of Chemical Sciences, University of Auckland, Auckland, New Zealand.

<sup>3</sup> Centre for Brain Research, University of Auckland, Auckland, New Zealand.

<sup>4</sup> Maurice Wilkins Centre for Molecular Biodiscovery. New Zealand.

<sup>5</sup> Department of Pharmacology and Toxicology, University of Otago, Dunedin, New Zealand.


**\* Correspondence:**

Christopher Walker


[cs.walker@auckland.ac.nz](mailto:cs.walker@auckland.ac.nz)

Debbie Hay

[dl.hay@auckland.ac.nz](mailto:dl.hay@auckland.ac.nz)



**Supplemental Figure 1.** Analytical RP-HPLC chromatogram of rimegepant (BMS-927711),  $t_R = 16.2$  min. Chromatographic separations were performed on a Thermo Scientific Dionex Ultimate 3000 HPLC using a Agilent C3, (3.5  $\mu\text{m}$ ; 3.0 x 150 mm) at a flow rate of 0.3 mL  $\text{min}^{-1}$  and a linear gradient of 5-95% B in 50 min at room temperature, *ca.* 2% B per min at a flow rate of 0.3 mL/min. Buffer A: H<sub>2</sub>O containing 0.1% TFA (v/v); Buffer B: acetonitrile containing 0.1% TFA (v/v). The peak at 2-5 min corresponds to the absorption of CH<sub>2</sub>Cl<sub>2</sub> (solvent).



**Supplemental Figure 2.** ESI-MS profile of rimegepant (BMS-927711); Ion polarity positive, 25 eV. ESI-MS ( $m/z$   $[M+H]^+$  calculated: 535.5; found: 535.2). The ESI-MS data is consistent with previous reports<sup>1</sup>.

1. Luo G, Chen L, Conway CM, Denton R, Keavy D, Signor L, et al. Discovery of (5S,6S,9R)-5-amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-yl 4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxylate (BMS-927711): an oral calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. *Journal of medicinal chemistry*. 2012;55(23):10644-51.